ArticlePoultry science2026
Research note: Dietary resveratrol alleviates necrotic enteritis in broilers associated with in vitro inhibition of Clostridium perfringens and enhancement of host intestinal barrier function.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotic enteritis (NE), primarily caused by Clostridium perfringens (CP), represents a significant threat to the poultry industry. Resveratrol (RES) possesses antimicrobial properties, yet its effects against CP and protective role in NE-challenged broilers remain incompletely understood. In this study, the in vitro antibacterial activity of RES against CP was evaluated, and its regulatory effects on bacterial gene expression were analyzed using prokaryotic RNA-seq. An NE infection model was established to investigate the effects of post-challenge dietary RES (125, 250, or 500 mg/kg) on growth performance, intestinal lesions, barrier function, and inflammatory responses. Resveratrol exhibited potent antibacterial activity against CP with a minimum inhibitory concentration of 0.16 mg/mL and dose-dependently inhibited bacterial sliding motility and biofilm formation. Transcriptome analysis revealed downregulation of peptidoglycan biosynthesis and energy metabolism pathways. In NE-challenged broilers, post-challenge dietary RES (250 mg/kg) improved average daily gain, reduced feed conversion ratio, attenuated intestinal lesions, decreased serum FITC-dextran concentrations, upregulated tight junction proteins (Occludin, ZO-1) and mucin (MUC2), and suppressed pro-inflammatory cytokines (IL-1β, IL-6). These findings demonstrate that RES shows in vitro antibacterial activity against CP and is associated with improved intestinal barrier function and reduced inflammation in NE-challenged broilers, supporting its potential as a functional feed additive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.